Lupin receives USFDA's establishment inspection report for its Nagpur facility

The establishment inspection report (EIR) was issued after the last inspection of the facility conducted from October 17-29, 2022, the company said in a regulatory filing. The injectable facility at Nagpur is designed to the highest quality standards and adheres to international regulations with advanced technology and equipment, Lupin Managing Director Nilesh Gupta said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/COrINB1
via IFTTT